Climb Bio Inc. Outlines 2026 Strategy With Multiple Clinical Trial Readouts, Expanded Pipeline in Immune-Mediated Diseases, and Financial Guidance Extending Operations Into 2028

Reuters · 3d ago

Please log in to view news